Skip to main content

Advertisement

Table 4 Association of positive rates of PRDX2 autoantibody and PRDX3 autoantibody with NPC patients’ clinicopathologic characteristics

From: Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma

  n PRDX2 autoantibody PRDX3 autoantibody Combination
Positive (%) χ 2 P Positive (%) χ 2 P Positive (%) χ 2 P
Gender
 Male 100 26 (26.0%) 1.564 0.211 25 (25.0%) 0.009 0.925 34 (34.0%) 1.138 0.286
 Female 29 11 (37.9%)    7 (24.1%)    13 (44.8%)   
Age
 ≤50 61 19 (31.1%) 0.344 0.558 16 (26.2%) 0.126 0.723 21 (34.4%) 0.201 0.654
 >50 68 18 (26.5%)    16 (23.5%)    26 (38.2%)   
T stage
 T1 + T2 65 16 (24.6%) 1.059 0.303 19 (29.2%) 1.375 0.241 27 (41.5%) 1.474 0.225
 T3 + T4 64 21 (32.8%)    13 (20.3%)    20 (31.3%)   
N stage
 N0 + N1 67 20 (29.9%) 0.093 0.760 15 (22.4%) 0.437 0.509 25 (37.3%) 0.047 0.829
 N2 + N3 62 17 (27.4%)    17 (27.4%)    22 (35.5%)   
M stage
 M0 122 34 (27.9%)   0.408* 30 (24.6%)   1.000* 44 (36.1%)   0.705*
 M1 7 3 (42.9%)    2 (28.6%)    3 (42.9%)   
Overall stage
 I + II (early stage) 40 11 (27.5%) 0.040 0.842 10 (25.0%) 0.001 0.973 16 (40.0%) 0.318 0.573
 III + IV (advanced stage) 89 26 (29.2%)    22 (24.7%)    31 (34.8%)   
  1. NPC nasopharyngeal carcinoma
  2. Statistical significance was determined by means of Chi-squared test or Fisher’s exact test (*)